SCHEMBL376648

SCHEMBL376648

CC(C)c1oc(-c2ccc(Cl)cc2Cl)nc1CCC(=O)c1ccc(S)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.49
PPARA Q07869 5/20 0.49
PPARD Q03181 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
HSD17B10 Q99714 2/20 0.39
TSHR P16473 2/20 0.39
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.39
TP53 P04637 1/20 0.36
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
KDM4E B2RXH2 1/20 0.34
FURIN P09958 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
DPP4 P27487 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376949 0.92 PPARG (0.51) PPARGPPARAPPARDSMN1; SMN2NPC1
SCHEMBL2463029 0.91 PPARG (0.51) PPARGPPARAPPARDSMN1; SMN2NPC1
SCHEMBL13296176 0.91 PPARG (0.52) PPARGPPARAPPARDSMN1; SMN2NPC1
SCHEMBL2460888 0.86 PPARG (0.52) PPARGPPARAPPARDSMN1; SMN2NPC1
SCHEMBL24658609 0.84 PPARG (0.56) PPARGPPARAPPARDSMN1; SMN2NPC1
SCHEMBL30003432 0.84 PPARG (0.56) PPARGPPARAPPARDSMN1; SMN2NPC1
SCHEMBL2465292 0.84 PPARG (0.50) PPARGPPARAPPARDSMN1; SMN2NPC1
SCHEMBL377168 0.84 PPARA (0.52) PPARGPPARAPPARDSMN1; SMN2NPC1
SCHEMBL1765972 0.84 PPARA (0.69) PPARGPPARAPPARDSMN1; SMN2MAPT
SCHEMBL12732396 0.83 PPARG (0.57) PPARGPPARAPPARDSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARG 2/4885PPARA 3/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.